Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 3, 2010, Pages 616-618

  Wanaka, K ^a   Matsuo, T ^b   Matsuo, M ^c   Kaneko, C ^a   Miyashita, K ^a   Asada, R ^c   Matsushima, H ^d   Nakajima, Y ^d  

^a Kobe Research Projects on Thrombosis and Haemostasis   (Japan)

^b HYOGO PREFECTURAL AWAJI HOSPITAL   (Japan)

^c HYOGO CANCER CENTER   (Japan)

^d KOBE CITY MEDICAL CENTER WEST HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; DRUG ANTIBODY; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NAFAMSTAT MESILATE;

ADULT; AGED; ANTIBODY TITER; ARTIFICIAL KIDNEY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG EXPOSURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN CELL; LETTER; MALE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SEROCONVERSION; THROMBOCYTE COUNT; UREMIA;

AGED; AGED, 80 AND OVER; ANTIBODIES; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PLATELET AGGREGATION; PLATELET FACTOR 4; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; THROMBOCYTOPENIA; THROMBOSIS; TIME FACTORS; UREMIA;

EID: 77949280661     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03734.x     Document Type: Letter

References (11)

1. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996, 101:502-7.
2. Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet 1982, 2:1246-9.
3. Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992, 68:95-6.
4. Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 1996, 28:82-5.
5. Matsuo T, Kobayashi H, Matsuo M, Wanaka K, Nakamoto H, Matsushima H, Sakai R. Frequency of anti-heparin-PF4 complex antibodies (HIT antibodies) in uremic patients on chronic intermittent hemodialysis. Pathophysiol Haemost Thromb 2006, 35:445-50.
6. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001, 344:1286-92.
7. Matsuo T, Matuo M, Wanaka K, Sakai R. Heparin re-exposure after heparin-induced thrombocytopenia in a chronic hemodialysis patient. Clin Lab Haematol 2003, 25:333-4.
8. Matsuo T, Kusano H, Wanaka K, Ishihara M, Oyama A. Heparin-induced thrombocytopenia in a uremic patient requiring hemodialysis: an alternative treatment and reexposure to heparin. Clin Appl Thromb Hemost 2007, 13:182-7.
9. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993, 69:344-50.
10. Akizawa T, Kinugasa E, Nakayama F, Kitaoka T, Koshikawa S. Clinical benefits of nafamostat mesilate as an anticoagulant for high bleeding risk hemodialysis. Artif Organs 1991, 14(Suppl. 4):209-12.
11. Akizawa T, Koshikawa S, Ota K, Kazama M, Mimura N, Hirasawa Y. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron 1993, 64:376-81.